Tirzepatide
ApprovedLY3298176
By Eli Lilly
Aliases: MounjaroZepbound
Source: Company Disclosure·Trials: 4
Modality
Peptide
MOA
GLP-1/GIP Dual Agonist
Target
GLP-1R
Pathway
Incretin
T2DObesity
Development Pipeline
Preclinical
~Feb 2013
→ ~May 2014
Phase 1
~Aug 2014
→ ~Nov 2015
Phase 2
~Feb 2016
→ ~May 2017
Phase 3
~Aug 2017
→ ~Nov 2018
NDA/BLA
~Feb 2019
→ ~May 2020
Approved
Aug 2020
→ Jan 2029
ApprovedCurrent
NCT07799388
541 pts·Obesity
2021-05→TBD·Recruiting
NCT05362003
475 pts·T2D
2020-08→2029-01·Recruiting
NCT03620127
112 pts·T2D
2021-06→2025-11·Not yet recruiting
+1 more trial
2,927 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2025-11-115mo agoPh3 Readout· T2D
2026-06-283mo awayPh3 Readout· T2D
2029-01-162.8y awayPh3 Readout· T2D
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
Approved
Recruit…
Approved
Recruit…
Approved
Not yet…
Approved
Complet…
Catalysts
Ph3 Readout
2025-11-11 · 5mo ago
T2D
Ph3 Readout
2026-06-28 · 3mo away
T2D
Ph3 Readout
2029-01-16 · 2.8y away
T2D
RecruitingCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07799388 | Approved | Obesity | Recruiting | 541 | EFS |
| NCT05362003 | Approved | T2D | Recruiting | 475 | CfB |
| NCT03620127 | Approved | T2D | Not yet recr... | 112 | PFS |
| NCT04877878 | Approved | T2D | Completed | 1799 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| 600-1653 | Jiangsu Hengrui | NDA/BLA | GLP-1R |